Vanguard Group Inc. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD

Vanguard Group Inc. reduced its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 0.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,179,371 shares of the biopharmaceutical company’s stock after selling 84,869 shares during the period. Vanguard Group Inc. owned 9.00% of ACADIA Pharmaceuticals worth $323,928,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 11.2% in the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 534 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of ACADIA Pharmaceuticals by 0.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock valued at $1,964,000 after buying an additional 626 shares during the period. GAMMA Investing LLC increased its holdings in shares of ACADIA Pharmaceuticals by 25.8% during the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after buying an additional 690 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 756 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 885 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the sale, the executive vice president directly owned 7,609 shares of the company’s stock, valued at approximately $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $24.56 on Friday. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 8.72 and a beta of 0.66. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $28.35. The business has a fifty day moving average of $25.53 and a 200-day moving average of $24.45.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 13.96%. The firm had revenue of $298.00 million during the quarter, compared to analyst estimates of $292.54 million. During the same quarter in the prior year, the firm posted $0.86 EPS. ACADIA Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. On average, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ACAD shares. Citizens Jmp increased their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the company a “market outperform” rating in a research note on Thursday. Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $29.00 to $35.00 in a report on Monday. TD Cowen lifted their target price on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada cut their target price on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.74.

ACADIA Pharmaceuticals News Summary

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.